SEARCH

SEARCH BY CITATION

References

  • 1
    Spechler SJ. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 249.
  • 2
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 9749.
  • 3
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 4
    Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44 (Suppl 2): S1S16.
  • 5
    Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis placebo-controlled randomized trial. Aliment Pharmacol Ther 2000; 14: 1103.
  • 6
    Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (3 Suppl. S): S408.
  • 7
    Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 8
    Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002; 37: 6427.
  • 9
    Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 92735.
  • 10
    Carlsson R, Galmiche J-P, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 47382.
  • 11
    Peura DA, Malfertheiner P. Chairmen's summary: dichotomies and directions in acid-related disorders. Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 7780.
  • 12
    Meineche-Schmidt V, Hauschildt Juhl H, Östergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004; 19: 90715.
  • 13
    Wahlqvist P, Junghard O, Higgins A, et al. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002; 20: 26777.
  • 14
    Pace F, Bollani S, Molteni P, et al. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on. Dig Liver Dis 2004; 36: 1115.
  • 15
    Lagergren J, Bergstrom R, Lindergren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 82531.
  • 16
    Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17–22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 3741.
  • 17
    Fass R, Ofmann JJ. Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 19018.
  • 18
    Solaymani-Dodaran M, Logan RFA, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 10704.
  • 19
    Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's esophagus and of H. pylori infection on healing of erosive GERD and symptom resolution in non-erosive GERD. Report from the ProGERD Study. Gut 2005; 54: 74651.
  • 20
    Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 21
    Levine D, Hamelin B, Magner D, et al. Correlation between patient demographics and heartburn severity with Los Angeles (LA) classification of erosive esophagitis. Am J Gastroenterol 1999; 94: 2591.